The Embleema Ambassador Program and Token sale are not open to residents and citizens of the USA, P.R. CHINA, CANADA, NEW ZEALAND, NORTH KOREA and any country within the list of non-cooperative countries from the TATF. We will be manually reviewing every Embleema’s Ambassador Program submissions.
48%Compensation of Data Owners storing Health Records
30%subscribers of the Founder’s token sale
15%Embleema Founders & Advisors
7%Marketing & Community Development Fund
25%Sales & Marketing
19% Product Development
14% Business Operations & Support
About Embleema Project
Imagine a world in which you can contribute to medical research and create safer, less expensive and faster new treatments against cancer and rares diseases. Imagine a tamper-proof, holistic, longitudinal and patient-centric worldwide health record interfacing with medical researchers, health regulators, physicians, care centers and the pharmaceutical industry.
We are a group of healthcare and technology veterans building it using cutting-edge technologies such as Blockchain and HL7 pharmaceutical industry standards. We are the only ICO project with a product already available on the market (PatientTruth), first major clients (Pierre Fabre, Servier) and a full support from the medical research community, the pharmaceutical industry and patient associations.
Embleema Inc. was founded in 2017 by Robert Chu, an industry veteran with 20+ years of experience and a distinguished career at IBM Corp. and IQVIA, the global leader in health data and clinical research. He has been joined by other digital health figures such as Alexis Normand, VP of Withings, Pr. John Halamka, MD and Professor at Harvard Medical School, CIO of Beth Isreal Deaconess, Adel B. Al-Saleh, CEO of T-Systems and Frederic Duchesne, CEO of Pierre Fabre Pharmaceuticals !
By participating to Embleema’s community and ICO, you will be a pioneer in a new era of blockchain-based medical research. Join us !
Head of Cosortium
User Experience Advisor
Business Development Executive
Prashant Khambekar, PhD
Chief Blockchain Development Executive
Frederic Duchesne, Pharm.D.
CEO of Pierre Fabre Pharmaceuticals
Vahan Simonyan, PhD
Chief Scientist - WHISE-Embleema Health Blockchain Consortium
Pr. John Halamka, MD
Professor of Innovation at Harvard Medical School
CEO of T-Systems and Board Member of Deutsche Telekom